2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2713 Glofitamab versus CD19-directed CAR T-cell therapy for relapsed or refractory large B-cell lymphoma: Effectiveness and recurrent infection burden in a real-world cohort

Siyuan Li, Jing Ruan, DO2, Danqing Zhao3, Yan Zhang, MD4, Wei Zhang5
1 Peking Union Medical College Hospital, Beijing, China
2 Peking Union Medical College Hospital, Beijing, China
3 Peking Union Medical College Hospital, Beijing, China
4 Peking Union Medical College Hospital, Beijing, China
5 Peking Union Medical College Hospital, Beijing, China

Introduction: CD19-directed chimeric antigen receptor (CAR) T-cell therapy and the CD20×CD3 bispecific antibody glofitamab are active in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), but they differ in treatment logistics and toxicity. Direct patient-level comparisons are limited, and per-patient infection proportions may miss recurrent events and changes in risk over time. We compared effectiveness, adverse events, and the frequency and temporal distribution of recurrent infections after these treatments.

Methods: We conducted a retrospective, single-center cohort study of 94 patients with R/R LBCL treated at Peking Union Medical College Hospital. Forty-four patients received glofitamab from February 2024 through March 2026 (28 monotherapy and 16 glofitamab-based combinations), and 50 received commercial CD19-directed CAR T-cell therapy from November 2021 through March 2026 (axicabtagene ciloleucel, n = 28; relmacabtagene autoleucel, n = 22). Response was assessed using the Lugano classification. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded using American Society for Transplantation and Cellular Therapy criteria. Overlap weighting based on age, sex, Eastern Cooperative Oncology Group performance status, Ann Arbor stage III-IV, and number of prior treatment lines was used to reduce measured confounding. Because proportional hazards assumptions were violated, progression-free survival (PFS) and overall survival (OS) were summarized using 24-month restricted mean survival time (RMST). Infections were analyzed both as the proportion of patients with at least 1 episode and as recurrent-event rates per patient-month. Weighted Poisson models compared days 0-30 with day 31 through month 24 and tested the treatment-by-period interaction. 

Results: Before weighting, glofitamab-treated patients were older, more often female, more likely to have stage III–IV disease, had worse performance status, and had received more lines of prior therapy. All five modeled covariates were balanced after weighting (absolute standardized mean differences <0.10). The weighted overall response rates were 63.3% with glofitamab and 81.3% with CAR T-cell therapy (P = 0.080), while the corresponding complete response rates were 34.3% and 74.3% (P < 0.001). Median follow-up was 17.4 and 17.6 months, respectively. The 24-month RMST for PFS was 12.9 versus 15.4 months (difference, −2.6 months; 95% CI, −7.4 to 2.3; P = 0.273), and that for OS was 19.9 versus 20.2 months (difference, −0.3 months; 95% CI, −3.9 to 3.5; P = 0.831). Weighted risks with glofitamab versus CAR T-cell therapy were 37.1% versus 64.8% for any-grade CRS (P = 0.030), 1.1% versus 14.9% for any-grade ICANS (P = 0.015), 14.1% versus 66.2% for grade ≥3 neutropenia (P < 0.001), and 5.4% versus 42.9% for grade ≥3 thrombocytopenia (P = 0.004). The weighted proportions of patients with at least one infection were 37.2% and 17.1%, respectively (risk ratio, 2.18; 95% CI, 0.93–5.12; P = 0.074). Across follow-up, 25 and 11 infection episodes occurred in the glofitamab and CAR T-cell groups, respectively. After weighting, the infection incidence rate was numerically higher with glofitamab than with CAR T-cell therapy (IRR for glofitamab versus CAR T-cell therapy, 2.44; 95% CI, 0.96–6.21; P = 0.060). In time-stratified analyses, the IRR for glofitamab versus CAR T-cell therapy was 1.30 during days 0–30 (95% CI, 0.44–3.85; P = 0.635) and 4.16 from day 31 through month 24 (95% CI, 1.24–13.92; P = 0.021). Infections occurring after day 30 were predominantly viral. However, the treatment-by-period interaction did not reach statistical significance (late-period-to-early-period ratio of IRRs, 3.20; 95% CI, 0.85–12.02; P = 0.085).

Conclusions: After overlap weighting, the CAR T-cell group had a higher complete response rate, whereas the glofitamab group had lower rates of CRS, ICANS, and severe neutropenia and thrombocytopenia. Survival comparisons remained inconclusive. The higher rate of predominantly viral infections after day 30 with glofitamab supports continued infection surveillance beyond the early treatment period.

Siyuan Li: No relevant conflicts of interest to declare.